We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.85 | 2.80 | 2.90 | 2.85 | 2.85 | 2.85 | 515,871 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.17 | 135.84M |
From Apr 2019 to Apr 2024
TIDMAGY
RNS Number : 1587V
Allergy Therapeutics PLC
23 October 2014
23 October 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Annual Report and Accounts
Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company, announces that the Annual Report and Accounts of the Company for the year ended 30 June 2014 and Notice of Annual General Meeting have been posted to shareholders.
The Annual Report and Accounts and Notice of the Annual General Meeting are available on the Company's website in the Investor Relations section. They can be located at http://www.allergytherapeutics.com/Reports%20and%20Presentations%20Sub.aspx for the Annual Report and Accounts and http://www.allergytherapeutics.com/AGM.aspx for the Notice of the Meeting.
For further information
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director Peel Hunt LLP +44 (0) 20 7418 8900 James Steel Clare Terlouw FTI Consulting +44 (0) 20 3727 1000 Simon Conway Victoria Foster Mitchell
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSBSBDGLBDBGSX
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
